RxDoctor Payments DataLook up a doctor →

Thomas Hughes, MD

Neurology · Mt. Pleasant, SCNPI 1831379213

Payments from drug & device makers

$101,603in general payments, 2019–2025

Across 1,701 payments — averaging $59.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$29K
  • Biogen$20K
  • Sanofi$13K
  • Biohaven Pharmaceuticals, Inc.$10K
  • Biohaven Pharmaceutical Holding Company Ltd.$4K
  • AbbVie$2K
  • plus $23K from 54 others

What the payments were for

  • Consulting fees$8,9769%
  • Speaking & faculty fees$59,96859%
  • Grants$440%
  • Travel & lodging$1,5872%
  • Food & beverage$30,89430%
  • Education$1340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC110$28,527
Biogen128$20,315
Sanofi50$12,891
Biohaven Pharmaceuticals, Inc.17$10,003
Biohaven Pharmaceutical Holding Company Ltd.10$4,033
AbbVie(2 entities)159$2,057
EMD Serono, Inc.111$2,041
Amgen(2 entities)62$1,465
Novartis95$1,442
Teva Pharmaceuticals USA, Inc.87$1,361
Genentech USA, Inc.63$1,051
Acadia Pharmaceuticals Inc48$979
UCB, Inc.50$902
TG Therapeutics, Inc.39$902
AstraZeneca(2 entities)25$775
Eisai Inc.38$728
Amneal Pharmaceuticals LLC37$723
SK Life Science, Inc.31$723
Neurocrine Biosciences, Inc.44$706
Supernus Pharmaceuticals, Inc.28$619
Argenx US, Inc.27$592
Otsuka America Pharmaceutical, Inc.42$591
Lundbeck LLC27$590
CSL Behring18$535
Johnson & Johnson24$522
Pfizer24$473
Bristol Myers Squibb37$406
Avanir Pharmaceuticals, Inc.23$395
Hyperfine Operations, Inc.1$390
Vanda Pharmaceuticals Inc.13$350
Takeda Pharmaceuticals U.S.A., Inc.14$324
Mallinckrodt Hospital Products Inc.15$311
Kyowa Kirin, Inc.18$309
Avadel CNS Pharmaceuticals, LLC17$300
Axsome Therapeutics, Inc.13$290
Acorda Therapeutics, Inc10$207
Harmony Biosciences LLC11$197
MDD US Operations, LLC11$188
Adamas Pharmaceuticals, Inc.10$177
Jazz Pharmaceuticals Inc.8$172
Assertio Therapeutics, Inc.13$169
Grifols USA, LLC9$169
Scilex Pharmaceuticals Inc.7$143
Merz Pharmaceuticals, LLC4$101
Currax Pharmaceuticals LLC7$100
Hospira, Inc.4$97
Tanabe Pharma America, Inc.6$93
Banner Life Sciences, LLC5$91
Xeris Pharmaceuticals, Inc.1$87
Amylyx Pharmaceuticals, Inc.3$81
Alnylam Pharmaceuticals Inc.4$74
GE HealthCare3$73
Almatica Pharma LLC4$71
Mallinckrodt Enterprises LLC3$65
Sumitomo Pharma America, Inc.4$54
Merz North America, Inc.2$51
E.r. Squibb & Sons, L.L.C.3$47
Sanofi-aventis U.S. LLC2$44
Aquestive Therapeutics, Inc.2$43
Abbott2$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,603 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,803,562
Medicare patients
1,000
Services billed
201,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate21$104,186
ZeposiaOzanimod Hydrochloride11$97,788
Kesimpta PenOfatumumab11$96,091
UbrelvyUbrogepant40$60,762
NuedextaDextromethorphan Hbr/Quinidine23$46,647
Nurtec OdtRimegepant Sulfate31$34,746
Ajovy AutoinjectorFremanezumab-Vfrm26$20,604
Aimovig AutoinjectorErenumab-Aooe19$19,984
RytaryCarbidopa/Levodopa23$18,621
Memantine Hcl461$12,878
Dalfampridine ErDalfampridine27$11,007
Carbidopa-LevodopaCarbidopa/Levodopa243$8,761
Gabapentin285$5,590
Lacosamide69$5,443
Primidone138$5,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$979$104,18621 claims
E.r. Squibb & Sons, L.L.C.Zeposia$47$97,78811 claims
AbbVieUbrelvy$2,057$60,76240 claims
Avanir Pharmaceuticals, Inc.Nuedexta$395$46,64723 claims
PfizerNurtec Odt$473$34,74631 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$723$19,85240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 270 neurology providers in South Carolina.

Other neurology in Mt. Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →